medigraphic.com

2007, Número S4

<< Anterior Siguiente >>

Arch Cardiol Mex 2007; 77 (S4)


Regulación antitrombótica por la fibrinólisis

Peña DA, Cruz RD, Pérez MÓ, García TJJ, Arce FM, Vargas AG

Idioma: Español
Referencias bibliográficas: 59
Paginas: 82-87
Archivo PDF: 116.36 Kb.


RESUMEN

En este trabajo se resalta la presencia del sistema fibrinolítico en diferentes mecanismos fisiológicos en especial en la regulación antitrombótica de la hemostasia. Se describe el mecanismo de activación del plasminógeno por los activadores tanto sobre la fibrina como en la superficie de las células; la inhibición de los activadores; el papel del inhibidor del activador en las alteraciones metabólicas; las consecuencias fisiopatológicas de los trastornos de la fibrinólisis.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Rosenberg R, Aird W: Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J of Med 1999; 20: 1555-64.

  2. Knowles RG, Moncada S: Nitric oxide as a signal in blood vessels. TIBS 1992; 17: 399-402.

  3. Jin RC, Voetsch B, Loscalzo J: Endogenous mechanisms of inhibition of platelet function. Microcirculation 2005; 12: 247-58.

  4. Hermann M: Cyclooxygenase-2 and nitric oxide. J Cardiovasc Pharmacol 2006; 47 Suppl 1: S21-5.

  5. Aikawa J, Esko JD: Molecular cloning and expression of a third member of the heparan sulfate/heparin GlcNAc N-deacetylase/ N-sulfotransferase family. J Biol Chem 1999; 274: 2690-5.

  6. Van de Wouwer M, Collen D, Conway EM: Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004; 24: 1374-83.

  7. Furie B, Furie BC: Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-806.

  8. Bouma BN, Mosnier LO: Thrombin activatable fibrinolysis inhibitor (TAFI)-How does thrombin regulate fibrinolysis? Ann Med 2006; 38(6): 378-88.

  9. Collen D, Lijnen HR: Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost 2004; 2: 541-6.

  10. Wiel E, Vallet B, ten Cate H: The endothelium in intensive care. Crit Care Clin 2005; 21: 403-16.

  11. Neurath H: Proteolytic processing and physiological regulation. TIBS 1989; 14: 268-271.

  12. Wiman B, Hamsten A: The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost 1990; 16: 207-16.

  13. Collen D, Lijnen HR: The fibrinolytic system in man. Crit Rev Oncol Hematol 1986; 4: 249-301.

  14. Anglés-Cano E: Overview on fibrinolysis: plasminogen activation pathway on fibrin and cell surfaces. Chem Phys Lipids 1994; 67: 353-62.

  15. Dobrovolsky AB, Titaeva EV: The fibrinolysis System: regulation of activity and physiology functions of its main components. Biochemistry 2002; 67: 99-108.

  16. Cesarman-Maus G, Hajjar KA: Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129: 307-21.

  17. Werb Z, Mainardi CL, Vater CA, Harris ED: Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role for plasminogen activator. N Engl J Med 1977; 296: 1017-23.

  18. Ho-Tin-Noe B, Rojas G, Vranckx R, Lijnen HR, Angles-Cano E: Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis. FEBS J 2005; 272: 3387-400.

  19. Daci E, Udagawa N, Martin TJ, Bouillon R, Carmeliet G: The role of the plasminogen system in bone resorption in vitro. J Bone Miner Res. 1999; 14: 946-52.

  20. Raikkonen K, Lassila R, Keltikangas-Jarvinen L, Hautanen A: Association of chronic stress with plasminogen activator inhibitor-1 in healthy middle-aged men. Arterioscler Thromb Vasc Biol 1996; 16: 363-7.

  21. Cho SH, Ryu CH, Oh CK: Plasminogen activator inhibitor-1 in the pathogenesis of asthma. Exp Biol Med 2004; 229: 138-46.

  22. Hertig A, Berrou J, Allory Y, Breton L, Commo F, Costa De Beauregard MA, et al: Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. FASEB J 2003; 17: 1904-6.

  23. Van Ness K, Chobaz-Peclat V, Castellucci M, So A, Busso N: Plasminogen activator inhibitor type-1 deficiency attenuates murine antigen-induced arthritis. Rheumatology (Oxford) 2002; 41(2): 136-41.

  24. Lijnen HR: Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.

  25. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA: The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996; 271: 10079-86.

  26. Nakagami Y, Abe K, Nishiyama N, Matsuki N: Laminin degradation by plasmin regulates long-term potentiation. J Neurosci 2000; 20: 2003-10.

  27. Kost C, Benner K, Stockmann A, Linder D, Preissner KT: Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor. Eur J Biochem 1996; 236: 682-8.

  28. Lijnen HR: Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 2004; 33: 275-81.

  29. Samis JA, Ramsey GD, Walker JB, Nesheim ME, Giles AR: Proteolytic processing of human coagulation factor IX by plasmin. Blood 2000; 95: 943-51.

  30. Schatteman KA, Goossens FJ, Scharpe SS, Hendriks DF: Proteolytic activation of purified human procarboxypeptidase. U Clin Chim Acta 2000; 292: 25-40.

  31. Wallace EM, Perkins SJ, Sim RB, Willis AC, Feighery C, Jackson J: Degradation of C1-inhibitor by plasmin: implications for the control of inflammatory processes. Mol Med 1997; 3: 385-96.

  32. Sato Y, Rifkin DB: Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol 1989; 109: 309-15.

  33. Campbell PG, Novak JF, Yanosick TB, McMaster JH: Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 1992; 130: 1401-12.

  34. Hervio LS, Coombs GS, Bergstrom RC, Trivedi K, Corey DR, Madison EL: Negative selectivity and the evolution of protease cascades: the specificity of plasmin for peptide and protein substrates. Chem Biol 2000; 7: 443-53.

  35. Wang N, Zhang L, Miles L, Hoover-Plow J: Plasminogen regulates pro-opiomelanocortin processing. J Thromb Haemost. 2004; 2: 785-96.

  36. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, et al: The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7: 59-64.

  37. Gveric D, Herrera BM, Cuzner ML: tPA receptors and the fibrinolytic response in multiple sclerosis lesions. Am J Pathol 2005; 166: 1143-51.

  38. Tsutsumi S, Saito T, Sakata T, Mlyata T, Ichinose A: Genetic diagnosis of dysplasminogenemia: detection of an Ala601-Thr mutation in 118 out of 125 families and identification of a new Asp676-Asn mutation. Thromb Haemost. 1996; 76: 135-8.

  39. Kwaan HC, Nabhan C: Hereditary and acquired defects in the fibrinolytic system associated with thrombosis. Hematol Oncol Clin North Am 2003; 17: 103-14.

  40. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183-90.

  41. Crowther MA, Roberts J, Roberts R, Johnston M, Stevens P, Skingley P, et al: Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost 2001; 85: 390-4.

  42. Prins MH, Hirsh J: A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med 1991; 151: 1721-31.

  43. Prins MH, Hirsh J: A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Am Heart J 1991; 122: 545-51.

  44. Dieval J, Nguyen G, Gross S, Delobel J, Kruithof EK: A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood. 1991; 77: 528-32.

  45. Agren A, Wiman B, Stiller V, Lindmarker P, Sten-Linder M, Carlsson A, et al: Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis. J Thromb Haemost 2006; 4: 201-8.

  46. Juhan-Vague I, Alessi MC, Mavri A, Morange PE: Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-9.

  47. Pannacciulli N, De Mitrio V, Marino R, Giorgino R, De Pergola G. Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects. Obes Res 2002; 10: 717-25.

  48. Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM: Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006; 113: 1753-9.

  49. Garcia-Touchard A, Henry TD, Sangiorgi G, Spagnoli LG, Mauriello A, Conover C, Schwartz RS: Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol 2005; 25: 1119-27.

  50. Liu Z, Li N, Diaz LA, Shipley M, Senior RM, Werb Z: Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 2005; 115: 879-87.

  51. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG: Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057-63.

  52. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-41.

  53. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U: Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000; 20: 2019-23.

  54. Zureik M, Robert L, Courbon D, Touboul PJ, Bizbiz L, Ducimetiere P: Serum elastase activity, serum elastase inhibitors, and occurrence of carotid atherosclerotic plaques: the etude sur le vieillissement arteriel (EVA) study. Circulation 2002; 105: 2638-45.

  55. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, et al: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potencial role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-9.

  56. Anglés-Cano E, de la Peña A, Loyau S: Inhibition of fibrinolysis by lipoprotein (a). Ann NY Acad of Sci 2001; 936: 261-75.

  57. de la Peña-Díaz A, Cardoso-Saldaña G, Zamora-González J, Barinagarrementeria F, Loyau S, Izaguirre R, Anglés-Cano E: Functional approach to investigate Lp(a) in ischaemic heart and cerebral diseases. Eur J of Clin Invest 2003; 33: 99-105.

  58. de la Peña-Díaz A, Izaguirre-Avila R, Anglés-Cano E: Lipoprotein Lp(a) and atherothrombotic disease. Arch Med Res 2000; 31: 353-359.

  59. Emanuele E, Peros E, Tomaino C, Feudatari E, Bernardi L, Binetti G, et al: Relation of apolipoprotein(a) size to alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord 2004; 18: 189-96.




2020     |     www.medigraphic.com